Gracell Biotechnologies (Gracell Biotechnologies) EBIT per Share : $-1.00 (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Gracell Biotechnologies EBIT per Share?

Gracell Biotechnologies's EBIT per Share for the three months ended in Sep. 2023 was $-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.00.

During the past 3 years, the average EBIT per Share Growth Rate was -7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Gracell Biotechnologies's EBIT per Share or its related term are showing as below:

GRCL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -34.2 Med: -21.05 Max: -7.9
Current: -7.9

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Gracell Biotechnologies was -7.90% per year. The lowest was -34.20% per year. And the median was -21.05% per year.

GRCL's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.4 vs GRCL: -7.90

Gracell Biotechnologies's EBIT for the three months ended in Sep. 2023 was $-9.09 Mil.

Gracell Biotechnologies EBIT per Share Historical Data

The historical data trend for Gracell Biotechnologies's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gracell Biotechnologies EBIT per Share Chart

Gracell Biotechnologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

-0.45

-1.00

-0.49

-1.07

-1.27

Gracell Biotechnologies Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial													-0.36	-0.27	-0.32	-0.30	-0.11

Gracell Biotechnologies EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Gracell Biotechnologies's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-86.17	/	67.668
=	-1.27

Gracell Biotechnologies's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.088	/	83.925
=	-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.00

Gracell Biotechnologies (NAS:GRCL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Gracell Biotechnologies EBIT per Share Related Terms

Thank you for viewing the detailed overview of Gracell Biotechnologies's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gracell Biotechnologies (Gracell Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gracell Biotechnologies Inc (NAS:GRCL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

218 Sangtian Street, Building 12, Block B, Phase II, Biobay Industrial Park, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.gracellbio.com

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.